Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial - The Lancet Diabetes & Endocrinology
Por um escritor misterioso
Descrição
Proposal for Standardization of Primary and Secondary Outcomes in
Proposal for Standardization of Primary and Secondary Outcomes in
Rosuvastatin in the Primary Prevention of Cardiovascular Disease
Lipid lowering effects of the CETP inhibitor obicetrapib in
Statins for Graves' orbitopathy: a new tool for prevention and
Recent advances in graves ophthalmopathy medical therapy: a
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label
High Serum Cholesterol Is a Novel Risk Factor for Graves
Biomedicines, Free Full-Text
Current and Emerging Treatment Strategies for Graves' Orbitopathy
Effect of dapagliflozin on the rate of decline in kidney function
Role of the mononuclear cell infiltrate in Graves' orbitopathy (GO
Long-term efficacy and safety of moderate-intensity statin with
de
por adulto (o preço varia de acordo com o tamanho do grupo)
